Last reviewed · How we verify
Topical Clindamycin
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Acne vulgaris, Bacterial skin infections, Rosacea (off-label).
At a glance
| Generic name | Topical Clindamycin |
|---|---|
| Also known as | Dalacin cream 2% |
| Sponsor | University of Toronto |
| Drug class | Lincosamide antibiotic |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin binds to the bacterial 50S ribosomal subunit and inhibits peptide bond formation, preventing bacterial protein synthesis. When applied topically, it reduces the population of Propionibacterium acnes and other bacteria on the skin surface, thereby reducing inflammation and comedone formation. This makes it effective for treating acne and other bacterial skin infections.
Approved indications
- Acne vulgaris
- Bacterial skin infections
- Rosacea (off-label)
Common side effects
- Skin irritation or dryness
- Contact dermatitis
- Erythema
- Peeling or scaling
Key clinical trials
- Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (PHASE2)
- Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel) (NA)
- Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris (PHASE4)
- Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Optimal Treatment of MRSA Throat Carriers (PHASE3)
- Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields (PHASE2)
- Effect of Topical Sinonasal Antibiotics (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical Clindamycin CI brief — competitive landscape report
- Topical Clindamycin updates RSS · CI watch RSS
- University of Toronto portfolio CI